Anavex Life Sciences Corp (AVXL)

[Hazel2323]

The initial data interpretation was not wrong, but it was confusing, so the company hired a former FDA statistician to put the same data into a format much better suited for accelerated FDA approval. While this confusion creates the uncertainty the market hates, the bottom line is that the company is now in a great position for Blarcamesine's accelerated approval. Buy with both hands now.